DE60235114D1 - Pyrazolamide zur anwendung in der behandlung von schmerz - Google Patents

Pyrazolamide zur anwendung in der behandlung von schmerz

Info

Publication number
DE60235114D1
DE60235114D1 DE60235114T DE60235114T DE60235114D1 DE 60235114 D1 DE60235114 D1 DE 60235114D1 DE 60235114 T DE60235114 T DE 60235114T DE 60235114 T DE60235114 T DE 60235114T DE 60235114 D1 DE60235114 D1 DE 60235114D1
Authority
DE
Germany
Prior art keywords
pain
treatment
compositions
methods
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60235114T
Other languages
English (en)
Inventor
Robert Nelson Atkinson
Michael Francis Gross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icagen Inc
Original Assignee
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen Inc filed Critical Icagen Inc
Application granted granted Critical
Publication of DE60235114D1 publication Critical patent/DE60235114D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60235114T 2001-11-01 2002-11-01 Pyrazolamide zur anwendung in der behandlung von schmerz Expired - Lifetime DE60235114D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33595801P 2001-11-01 2001-11-01
PCT/US2002/035172 WO2003037274A2 (en) 2001-11-01 2002-11-01 Pyrazole-amides and-sulfonamides

Publications (1)

Publication Number Publication Date
DE60235114D1 true DE60235114D1 (de) 2010-03-04

Family

ID=23313962

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60235114T Expired - Lifetime DE60235114D1 (de) 2001-11-01 2002-11-01 Pyrazolamide zur anwendung in der behandlung von schmerz

Country Status (8)

Country Link
US (2) US7223782B2 (de)
EP (1) EP1451160B1 (de)
AT (1) ATE455104T1 (de)
AU (1) AU2002363250A1 (de)
CA (1) CA2465207C (de)
DE (1) DE60235114D1 (de)
ES (1) ES2338539T3 (de)
WO (1) WO2003037274A2 (de)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205307B2 (en) * 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
MXPA05000200A (es) * 2002-07-02 2005-06-06 Schering Corp Nuevos antagonistas del receptor neuropeptido y y5.
US7186735B2 (en) * 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
EP1388535A1 (de) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylierte Arylcycloalkylamine und ihre Anwendung als Arzneimittelwirkstoff
GB0219961D0 (en) * 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
JP2006519755A (ja) * 2002-11-20 2006-08-31 ロレアル ピラゾール−カルボキシアミドを含有する毛髪の手入れ用又は睫毛用の組成物、毛髪及び睫毛の成長を刺激し、及び／又は抜毛を防止するためのそれらの使用
AU2004209495A1 (en) 2003-02-07 2004-08-19 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
US7531558B2 (en) * 2003-02-14 2009-05-12 Glaxo Group Limited Carboxamide derivatives
SE0300705D0 (sv) * 2003-03-14 2003-03-14 Biolipox Ab New compounds
WO2004089896A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
AR045979A1 (es) * 2003-04-28 2005-11-23 Astrazeneca Ab Amidas heterociclicas
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
SI1618092T1 (sl) * 2003-05-01 2010-11-30 Bristol Myers Squibb Co Aril substituirane pirazolamidne spojine uporabnekot kinazni inhibitorji
WO2004108133A2 (en) * 2003-06-05 2004-12-16 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
JP2007506741A (ja) * 2003-09-23 2007-03-22 メルク　エンド　カムパニー　インコーポレーテッド 向代謝性グルタミン酸受容体のピラゾール系調節剤
DE10360369A1 (de) * 2003-12-22 2005-07-14 Bayer Cropscience Ag Amide
AU2005214375A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
US7687533B2 (en) 2004-03-18 2010-03-30 Pfizer Inc. N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides
EA201890903A9 (ru) * 2004-09-02 2021-11-10 Дженентек, Инк. Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
JP2008513426A (ja) 2004-09-20 2008-05-01 バイオリポックス エービー 炎症の治療に有用なピラゾール化合物
US20080090836A1 (en) * 2004-09-20 2008-04-17 Peter Nilsson Pyrazole Compounds Useful In The Treatment Of Inflammation
AU2005293336B2 (en) 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
WO2006089076A2 (en) 2005-02-18 2006-08-24 Neurogen Corporation Thiazole amides, imidazole amides and related analogues
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
US20090131412A1 (en) * 2005-06-07 2009-05-21 Dainippon Sumitomo Pharma Co., Ltd. Novel 2-quinolone derivative
CN1884262B (zh) * 2005-06-24 2014-06-25 中国人民解放军军事医学科学院毒物药物研究所 4-氨基哌啶类化合物及其医药用途
JP5261176B2 (ja) * 2005-08-16 2013-08-14 アイカジェン， インコーポレイテッド 電位作動型ナトリウムチャンネル阻害剤
EP1772449A1 (de) * 2005-10-05 2007-04-11 Bayer CropScience S.A. N-alkyl-heterocyclische carboxamide Derivate
WO2007073432A2 (en) * 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
EP1943234A1 (de) * 2005-10-31 2008-07-16 Biolipox AB Triazolverbindungen als lipoxygenaseinhibitoren
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
EP1943225A1 (de) * 2005-11-01 2008-07-16 Biolipox AB Bei der behandlung von entzündungen geeignete pyrazole
EP1787981A1 (de) * 2005-11-22 2007-05-23 Bayer CropScience S.A. Neue N-phenethylcarboxamidderivate
JP2009523748A (ja) * 2006-01-18 2009-06-25 シエナ ビオテク ソシエタ ペル アチオニ α７ニコチン性アセチルコリン受容体の調節物質およびそれらの治療への使用
FR2897061B1 (fr) 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
SI1999114T1 (sl) 2006-03-22 2015-10-30 F. Hoffmann-La Roche Ag Pirazoli kot 11-beta-hsd-1
US8841483B2 (en) 2006-04-11 2014-09-23 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
JP5290965B2 (ja) * 2006-06-08 2013-09-18 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト Ｎ−（１−アルキル−２−フェニルエチル）−カルボキサミド誘導体と、それを殺真菌剤として利用する方法
EA200900072A1 (ru) 2006-07-07 2009-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
CA2657247A1 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
EP2065369A4 (de) * 2006-08-23 2011-12-28 Astellas Pharma Inc Harnstoffverbindung oder salz davon
BRPI0718515A2 (pt) 2006-09-25 2013-11-19 Boehringer Ingelheim Int Compostos que modulam o receptor cb2
EP2079728B1 (de) * 2006-10-10 2013-09-25 Amgen Inc. N-arylpyrazolverbindungen zur verwendung gegen diabetes
TW200833695A (en) 2006-10-12 2008-08-16 Xenon Pharmaceuticals Inc Use of spiro-oxindole compounds as therapeutic agents
WO2008046084A2 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents
US8173638B2 (en) * 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
JP2010043004A (ja) * 2006-12-06 2010-02-25 Dainippon Sumitomo Pharma Co Ltd 新規２環性複素環化合物
CL2008000512A1 (es) 2007-02-22 2008-08-29 Bayer Cropscience Sa Compuestos derivados de n-(3-fenilpropil)carboxamida; procedimiento de preparacion de dichos compuestos; composicion fungicida; y metodo para combatir de forma preventiva o curativa los hongos fitopatogenos de cultivos.
WO2008135826A2 (en) * 2007-05-03 2008-11-13 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
CL2008001647A1 (es) 2007-06-08 2008-10-10 Syngenta Participations Ag Compuestos derivados de feniletil-amida de acido-1h-pirazol-4-carboxilico; compuestos derivados de (feniletil)amina; metodo para controlar o prevenir la infestacion de plantas por parte de microorganismos fitopatogenos; y composicion para el control
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
ES2523196T3 (es) * 2007-07-13 2014-11-21 Icagen, Inc. Inhibidores de los canales de sodio
EP2178865B1 (de) 2007-07-19 2015-08-19 Lundbeck, H., A/S Fünfteilige heterozyklische amide und entsprechende verbindungen
US7977358B2 (en) 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
EP2212290B1 (de) 2007-10-11 2014-12-03 Vertex Pharmaceuticals Incorporated Als inhibitoren von spannungsabhängigen natriumkanälen geeignete arylamide
WO2009049181A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
CA2701946A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
CA2704684A1 (en) 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
CA2714591A1 (en) 2008-02-13 2009-08-20 Eisai R&D Management Co., Ltd. Bicycloamine derivative
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
US9206143B2 (en) 2008-03-19 2015-12-08 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US9212155B2 (en) 2008-03-19 2015-12-15 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
JP5216912B2 (ja) * 2008-04-29 2013-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物
CA2722811C (en) * 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
UY31907A (es) 2008-06-19 2010-01-29 Takeda Pharmaceutical Compuesto heterociclico y su uso
CA2730037A1 (en) 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
PE20110397A1 (es) 2008-09-25 2011-07-01 Boehringer Ingelheim Int Compuestos que modulan selectivamente el receptor cb2
EP2346868B1 (de) * 2008-09-26 2016-01-27 Boehringer Ingelheim International Gmbh Azaindazolverbindungen als ccr1-rezeptorantagonisten
AU2009295855A1 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh Antiproliferative compounds
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN103664973B (zh) 2008-10-17 2017-04-19 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
WO2010080357A1 (en) * 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
CA2761639C (en) 2009-05-29 2016-06-07 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
DE102009036604A1 (de) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
JP2013505295A (ja) 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節する化合物
NZ712378A (en) 2009-10-14 2017-05-26 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
CA2778060A1 (en) 2009-10-21 2011-04-28 Boehringer Ingelheim International Gmbh Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
JP5542214B2 (ja) 2009-10-27 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしての複素環化合物
JP2013512954A (ja) * 2009-12-08 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換インダゾール及びアザインダゾール化合物の生成に有効な中間体の合成方法
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
SG183126A1 (en) 2010-02-26 2012-09-27 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
JP5746228B2 (ja) 2010-03-05 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節するテトラゾール化合物
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター
EP2552907B1 (de) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazole
EP2563787B1 (de) 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Azaindazolamidverbindungen als ccr1-rezeptor-antagonisten
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
US9302991B2 (en) * 2010-10-18 2016-04-05 Raqualia Pharma Inc. Arylamide derivatives as TTX-S blockers
WO2012052459A1 (en) * 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
EP2630126B1 (de) 2010-10-21 2015-01-07 Glaxo Group Limited Pyrazolverbindungen gegen allergie-, immun- und entzündungserkrankungen
WO2012061926A1 (en) * 2010-11-08 2012-05-18 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
AR083987A1 (es) 2010-12-01 2013-04-10 Bayer Cropscience Ag Amidas de acido pirazolcarboxilico utiles para la reduccion de la contaminacion de micotoxina en las plantas
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
JP5684406B2 (ja) 2010-12-23 2015-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのピラゾロピペリジン化合物
MX347952B (es) 2011-05-13 2017-05-19 Array Biopharma Inc Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka.
WO2012177263A1 (en) 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
DE102011055815A1 (de) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
WO2013138613A1 (en) 2012-03-16 2013-09-19 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
JP2015516976A (ja) * 2012-04-17 2015-06-18 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス処置のための化合物および方法
KR102067235B1 (ko) * 2012-04-25 2020-01-16 라퀄리아 파마 인코포레이티드 Ttx-s 차단제로서 아미드 유도체
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
CN103772284B (zh) * 2012-10-23 2015-08-12 沈阳感光化工研究院 一种4,5-二氨基-1-(2-羟乙基)吡唑硫酸盐的制备方法
CN102993097A (zh) * 2012-11-09 2013-03-27 贵州大学 吡唑酰胺类化合物及其应用
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
AU2013344886B2 (en) 2012-11-13 2017-06-29 Array Biopharma Inc. Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
WO2014078322A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
BR112015010875B1 (pt) 2012-11-13 2022-05-03 Array Biopharma Inc Compostos de n-pirrolidinil, n-pirazolil-ureia, tioureia, guanidina e cianoguanidina como inibidores de trka quinase, sua composição farmacêutica, seu uso e seu processo para preparação
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
MX2015008919A (es) 2013-01-10 2015-10-22 Gruenenthal Gmbh Carboxamidas basadas en pirazolilo i como inhibidores del canal de calcio activado por liberacion de calcio (crac).
AU2014204977A1 (en) 2013-01-10 2015-08-20 Grunenthal Gmbh Pyrazolyl-based carboxamides II as CRAC channel inhibitors
EP2803668A1 (de) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CA2923503A1 (en) * 2013-09-25 2015-04-02 Valorisation-Recherche Inhibitors of polynucleotide repeat-associated rna foci and uses thereof
US10835533B2 (en) 2014-05-15 2020-11-17 Array Biopharma Inc. 1 -((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor
EP3152199B1 (de) 2014-06-03 2018-08-15 Idorsia Pharmaceuticals Ltd Pyrazol- verbindungen und ihre verwendung als t-typ calciumkanalblocker
EP3193609A4 (de) * 2014-09-10 2018-02-28 Epizyme, Inc. Substituierte pyrrolidin-carboxamid-verbindungen
WO2016041892A1 (en) 2014-09-15 2016-03-24 Actelion Pharmaceuticals Ltd Triazole compounds as t-type calcium channel blockers
CN104402819B (zh) * 2014-09-22 2016-08-24 安徽农业大学 一类双吡唑酰胺衍生物的制备及其在治理水稻黑条矮缩病中的应用
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
ES2805528T3 (es) 2014-12-23 2021-02-12 Sma Therapeutics Inc Inhibidores de 3,5-diaminopirazol quinasa
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
WO2016202758A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
WO2016202756A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
WO2016202935A1 (en) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
DK3356345T3 (da) * 2015-09-30 2024-02-12 Max Planck Gesellschaft Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
WO2017063966A1 (en) 2015-10-13 2017-04-20 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds
JP6572392B2 (ja) 2015-12-18 2019-09-11 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 電位作動型ナトリウムチャネルにおいて選択的活性を有する、ヒドロキシアルキルアミンおよびヒドロキシシクロアルキルアミンで置換されたジアミン−アリールスルホンアミド化合物
US10882841B2 (en) 2016-03-01 2021-01-05 University Of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
HUE049918T2 (hu) 2016-05-31 2020-11-30 Kalvista Pharmaceuticals Ltd Pirazol-származékok mint plazma kallikrein inhibitorok
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
AU2017378487B2 (en) 2016-12-15 2022-03-31 The Regents Of The University Of California Compositions and methods for treating cancer
UA124977C2 (uk) 2016-12-16 2021-12-22 Ідорсія Фармасьютікалз Лтд Фармацевтична комбінація, яка містить блокатор кальцієвих каналів т-типу
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
CN110225781B (zh) * 2017-01-09 2022-05-17 辉诺生物医药科技（杭州）有限公司 噻唑衍生物及其应用
MX2019009242A (es) 2017-02-06 2019-09-13 Idorsia Pharmaceuticals Ltd Un proceso novedoso para la sintesis de 1-aril-1-trifluoro-metil-c iclopropanos.
US11491150B2 (en) 2017-05-22 2022-11-08 Intra-Cellular Therapies, Inc. Organic compounds
LT3716952T (lt) 2017-11-29 2022-04-11 Kalvista Pharmaceuticals Limited Vaisto formos, apimančios plazmos kalikreino inhibitorių
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2019243965A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Pyrazole derivatives as malt1 inhibitors
JP7296408B2 (ja) 2018-06-18 2023-06-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤としてのピラゾール誘導体
WO2020117626A1 (en) 2018-12-05 2020-06-11 Merck Sharp & Dohme Corp. 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN114044754A (zh) * 2021-11-23 2022-02-15 贵州大学 一类5-三氟甲基-4-吡唑衍生物的制备方法及其在抑制肿瘤细胞上的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4620865A (en) * 1983-11-07 1986-11-04 Eli Lilly And Company Herbicidal and algicidal 1,5-disubstituted-1H-pyrazole-4-carboxamides
US4589905A (en) * 1983-11-07 1986-05-20 Eli Lilly And Company Herbicidal and algicidal 1-aryl-5-cyano-1H-pyrazole-4-carboxamides
GB9424379D0 (en) * 1994-12-02 1995-01-18 Agrevo Uk Ltd Fungicides
US6020121A (en) 1995-09-29 2000-02-01 Microcide Pharmaceuticals, Inc. Inhibitors of regulatory pathways
US5688830A (en) 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
EP0923575B1 (de) 1996-08-29 2003-03-12 Takeda Chemical Industries, Ltd. Zyklische etherverbindungen als natriumkanal-modulatoren
AP9801302A0 (en) * 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..

Also Published As

Publication number Publication date
US20080064690A1 (en) 2008-03-13
EP1451160A4 (de) 2005-04-20
US20050049237A1 (en) 2005-03-03
WO2003037274A3 (en) 2003-10-30
EP1451160A2 (de) 2004-09-01
CA2465207C (en) 2011-01-04
WO2003037274A2 (en) 2003-05-08
ATE455104T1 (de) 2010-01-15
CA2465207A1 (en) 2003-05-08
EP1451160B1 (de) 2010-01-13
ES2338539T3 (es) 2010-05-10
US7223782B2 (en) 2007-05-29
AU2002363250A1 (en) 2003-05-12

Similar Documents

Publication Publication Date Title
DE60235114D1 (de) Pyrazolamide zur anwendung in der behandlung von schmerz
EP1506196A4 (de) Pyrazolopyrimidine
WO2003037890A3 (en) Piperidines
WO2007021941A3 (en) Inhibitors of voltage-gated sodium channels
MY169308A (en) Treatment of tnf? related disorders
SG152907A1 (en) Combinations for the treatment of inflammatory disorders
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
EP1463733A4 (de) Inhibitoren von mitotischem kinesin
WO2009012242A3 (en) Sodium channel inhibitors
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
HK1156515A1 (en) Pharmaceutical compositions and methods for accelerating wound healing
NO20035474D0 (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
WO2003049527A3 (en) Mitotic kinesin inhibitors
WO2004093814A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker
EA200501319A1 (ru) Способы лечения боли введением антагониста фактора роста нервов и нестероидного противовоспалительного средства и содержащие их композиции
RS13204A (en) Combination therapy for the treatment of cancer
MXPA02012626A (es) Bis-arilsufonas.
NO20052999L (no) Ny synergistisk kombinasjon omfattende roflumilast og formoterol
WO2007056099A3 (en) Inhibitors of ion channels
DE60213116D1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
MXPA03010406A (es) Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd.
EA200501865A1 (ru) Аналоги тиовольфраматов и их применение

Legal Events

Date Code Title Description
8364 No opposition during term of opposition